carbocisteine lysine
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2013 (NCT02015598)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
Carbocisteine is a mucolytic that reduces the viscosity of sputum and so can be used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing the sufferer to bring up sputum more easily. Carbocisteine reportedly scavenged H2O2, HOCl, OH+ and ONOO– in cell-free medium, inhibited ROS production in rat neutrophils, promoted GSH and HO-1 expression in cigarette smoke-exposed bronchial epithelial cells, and ameliorated oxidant-induced 16HBE cell apoptosis. Furthermore, carbocisteine was capable of attenuating the synthesis of pro-inflammatory cytokines following rhinovirus or respiratory syncytial virus infection. It was speculated that the efficacy of carbocisteine in COPD was more closely associated with its anti-oxidant and anti-inflammatory effects, than with mucolytic activity.
Chemistry & pharmacology
SMILES
N[C@@H](CSCC(=O)O)C(=O)O- Mol. weight
- 179.2 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL396416 ↗
Also known as
- ahr-3053
- ahr-3053
- bronchokod
- carbocistein
- carbocistein
- carbocisteine
- carbocisteine
- carbocisteine
- carbocisteine
- carbocisteine
- carbocisteine
- carbocisteine
- carbocisteine lysine
- carbocisteine lysine
- carbocisteine sodium
- carbocit
- carbocysteine
- carbocysteine
- carbocysteine
- carbocysteine
- chilvax
- (l)-2-amino-3-(carboxymethylthio)propionic acid
- (l)-2-amino-3-(carboxymethylthio)propionic acid
- l-3-((carboxymethyl)thio)alanine
- l-3-((carboxymethyl)thio)alanine
- l-carbocysteine
- l-carbocysteine
- l-(carboxymethyl)cysteine
- lisil
- lisomucil
- lj-206
- lj-206
- loviscol
- loviscol
- loviscol
- muciclar
- mucocis
- mucodyne
- mucodyne
- mucodyne
- mucodyne fte
- mucofan
- mucofan
- mucofan
- mucolase
- mucolex
- mucolex
- mucolex
- mucopront
- mucosol
- mucotab
- mukinyl
- pectdrill
- pectox
- pulmoclase
- pulmoclase
- pulmoclase
- reomucil
- rhinathiol
- rhinatiol
- (r)-s-(carboxymethyl)cysteine
- (r)-s-(carboxymethyl)cysteine
- s-carboxymethylcysteine
- s-carboxymethylcysteine
- s-carboxymethyl-l-cysteine
- s-carboxymethyl-l-cysteine
- s-(carboxymethyl)-(r)-cysteine
- s-(carboxymethyl)-(r)-cysteine
- thiodril
- transbronchin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06863376 | Phase 2 | Mar 1, 2025 | Tanta University |
| NCT04140214 | Phase 3 | Jun 27, 2018 | Queen's University, Belfast |
| NCT02858193 | Phase 1 | Jul 1, 2016 | Cross Research S.A., Dompe Pharmaceuticals |
| NCT01968434 | Phase 4 | Dec 1, 2013 | Technion University |
| NCT02015598 | N/A | Dec 1, 2013 | Guangzhou Medical University |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cross Research S.A. | For profit | 1 | 0 | 1 | 2016 |
| Dompe Pharmaceuticals | For profit | 1 | 1 | 1 | 2016 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Queen's University, Belfast | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Tanta University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Technion University | Academic/Hospital | 1 | 1 | 1 | 2013 |